Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2012.46.6896 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Initial PCV Chemotherapy Followed by Radiotherapy Is Associated With a Prolonged Response But Late Neurotoxicity in 20 Diffuse Low-Grade Glioma Patients.
Front Oncol
March 2022
Department of Neurology, Neurooncology Unit, CHRU, Nancy, France.
Background: Study RTOG 9802 in high-risk diffuse low-grade gliomas (DLGGs) showed the potential synergistic effect on survival of the procarbazine, CCNU, and vincristine (PCV) radiotherapy (RT) combination. Limited data on long-term neurocognitive impact and quality of life (QoL) have yet been reported.
Patients And Methods: We described a monocentric series of patients treated at first line by the combination of PCV immediately followed by RT between January 01, 1982 and January 01, 2017.
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
BMC Cancer
February 2021
Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.
Background: Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG). However, 1 year of PCV is associated with significant toxicities. In the pivotal RTOG 9802 randomised control trial, approximately half of the patients discontinued treatment after 6 months.
View Article and Find Full Text PDFArticle Synopsis
- The NRG Oncology/RTOG 9802 study demonstrated that patients with WHO low-grade glioma benefit from adjuvant chemoradiotherapy, showing improved survival compared to radiotherapy alone.
- A post hoc analysis evaluated the impact of molecular subgroups on patient outcomes, finding significant differences in progression-free survival (PFS) and overall survival (OS) based on molecular mutations.
- Specifically, treatment with postradiation chemotherapy (PCV) significantly improved PFS and OS for mutant groups, while showing no benefit for patients in the wild-type subgroup, highlighting the importance of molecular profiling in treatment decisions.
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Cancer Med
January 2020
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Purpose: The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy. This article aims to evaluate the evidence and rationale for the widespread use of TMZ instead of PCV for high-risk LGG.
Methods And Materials: We conducted a literature search utilizing PubMed for articles investigating the combination of radiotherapy and chemotherapy for high-risk LGG and analyzed the results of these studies.
Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis.
Anticancer Res
June 2019
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, U.S.A.
Background: RTOG 9802 identified a cohort of patients with age less than 40 years and undergoing gross total resection as having low-risk, low-grade glioma (LR-LGG). European Organization for Research and Treatment of Cancer studies have demonstrated additional prognostic features in this group. The aim of this study was to analyze clinical factors associated with overall survival (OS), identify a potentially higher risk group within LR-LGG, and investigate patterns of care for adjuvant therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!